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Alan Bennett (University of California, Davis):  This question is for Ricke Kress on citrus 
greening. I recall in the National Academy report some discussion of delivering a resistance 
trait through rootstocks. Is that being explored in terms of delivery through a transgenic 
rootstock, for citrus or other woody species?
Ricke Kress:  Yes. It is part of the industry-research effort. It’s a determination to elucidate 
the relative importance of the scion or the rootstock or both.
Chris Wozniak (US Environmental Protection Agency):  I have a question regarding some 
of the surveys a couple of you mentioned relative to people’s perception of putting DNA 
back into the same species and whether you want to call it intragenics or cisgenics or Innate 
technology or whatever. Do you think that the people answering those questions really 
understand the difference as to whether you are plopping in an ORF or a new promoter? 
Do they really understand differences in, say, the amount of the trait that will be expressed 
in your version of the plant versus where you are getting the gene from?
Haven Baker:  The answer is no.  
Wozniak:  That’s pretty much what I figured.
Carter:  We didn’t try to differentiate between transgenic, cisgenic and intergenic.
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Wozniak:  I’m curious because in years of talking with people who are in this research—and 
reviewing grant proposals—everybody seems to tout their own version of what is cisgenic 
and what is intergenic and why theirs is better than the last guy’s. One of the things that 
we have considered is that if you do manipulate control elements, promoter sequences, 
then you are dealing with a different scenario because then you are changing the tissue 
and expression pattern of that trait protein or whatever it is, as compared to, say, eating 
the same thing you have always been eating because the gene came from potato and it’s 
in potato. Whereas when you do those manipulations it’s not really the same, at least to 
some ways of thinking.
Baker:  Scientific distinctions are usually lost on the general population. It’s confusing 
if you use Google alerts of the reports of what you think the public perception is. Data 
generated by the International Food and Information Council is reasonably neutral—I 
hope—when they ask people, “Do you support biotech in your food?” They get answers 
similar to ours. Then you ask the next question, “Do you know if biotechnology is in your 
food?” and two thirds of Americans say they don’t know and another 0% say no. So you 
are asking for opinions on subjects that consumers are largely uninformed of and probably 
want to stay that way as long as it’s safe. So, yes, these distinctions get lost on the majority 
of the population, but 8% of people—it correlates highly with the organic crowd—are 
very against technology and very vocal. That’s generally who we think about and who we 
hear about. It’s a hard thing to get your arms around what people really think.
Audience Member:  My question is again related to cisgenic and intragenic versus trans-
genic. When you are dealing with USDA-APHIS, FDA and so on, does that make your 
life easier?
Neal Carter:  We never made the distinction. We just call it transgenic. The regulatory 
process essentially is the assessment of risk and the data package addresses that. If you 
can build a vector that is simpler, or do something that is going to require less data, than 
the regulatory process will be easier. But, at the end of the day, you have to address the risks.
Haven Baker:  One more thing on why we did what we did. In the case of potatoes—and 
also tomatoes—you’ve already had market failures. Growers have long memories and so 
do industry participants. We talk about the Innate™ technology, partly to differentiate it 
from past efforts. That’s not really geared toward the regulatory aspect. It’s geared towards 
consumers, and, in our case, towards industry.
Roger Beachy (Global Institute for Food Security, Saskatoon):  Two questions. We heard 
from oranges about $3. to $3.4 million for all the tests for regulatory approval of a new 
protein entry, and I didn’t hear that in apples. I wonder if you would comment on the 
differences there and what does that reflect? Then I want John Purcell to address the is-
sue of would you have done Bt sweet corn if you had to go through the whole process of 
deregulating the event rather than crossing it in?
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Carter:  From our perspective it’s hard to define regulatory costs. I’m not sure what is meant 
by that. A lot of the costs—such as for field trials—you will incur anyway. I think I heard 
Dennis say a quarter of a million dollars—that kind of range—nothing like three or four 
or five million. But we haven’t finished yet. Maybe we are going to see more costs.
Kress:  We have looked at what we feel we have to do to work our way through the process 
identifying all the potential tests and data collection and so on that we have to put into 
our package. We are going to do what we have to do. I also have a board of directors that 
is very interested in what we are doing as well, so I need to give them some insight as to 
how this can work.
Carter:  There’s an important distinction, in that we are not going through the EPA. 
Also I’m not including the cost of the field trials and the 0 years of field data that we 
generated that we wanted to have ourselves. I’m thinking more of the incremental cost 
of putting those data together and doing the statistics on it in a way, shape and form 
that the regulatory people wanted to see it done. Maybe there’s a few additional studies 
that we did, and then the sequencing of the events themselves. We hadn’t fully sequenced 
them, we relied on Southern data and we went ahead and sequenced them—just some 
extra things we did for regulatory purposes.
Kress: In the scheme of economics, the regulatory package might be the cheapest part. 
When we start to build these trees and to commercialize them and move into the growth 
side of it, it’s going to be expensive because with the new regulations on nursery opera-
tions, and so on, for every 00,000 trees in citrus right now it’s about a million dollars 
to build a structure to meet all the requirements and handle it all. There are 60 million 
trees in the state of Florida, so there’s a lot more to the puzzle.
Daniel Lineberger: There is a follow up question for John about sweet corn.
John Purcell:  Let me provide a little context first. At Monsanto, as a scientist, you feel 
fortunate because there are significant investments in R&D, but there is also a stringent 
process for every project, and one of the milestones it hits is when it goes into the regula-
tory phase, because that’s when you start assuming the regulatory costs. In each stage of 
the discovery process, we make priority decisions on which projects move forward. The 
challenge is in a lot of the vegetables. If you look at the number of markets in which we 
have to go for cultivation approvals alone. Look at tomatoes: It’s a big market opportu-
nity, but it’s not like corn, cotton and soybean. It’s a very distributive kind of market. 
It’s $500,000 to $ million at a time. So, when you look at those kinds of markets it’s 
difficult to say whether you go a product-development route that will require the regula-
tory piece. Looking at that many cultivation approvals and then the import approvals for 
where those products are flowing, the numbers don’t pencil out. Part of the stringency is 
what’s called APV: at present value. When you look at the cost of developing the product 
and what will be the eventual return, and then the other piece that is in there is the risk 
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adjustment on that, which is what is the chance of getting all those approvals in order to 
have that commercialization. So a lot of these vegetable products from the transgenics 
just don’t pencil out. The corn one—that’s an interesting question. We started with the 
approval and so it wasn’t a hard decision for us. I haven’t done the numbers but I’d be 
skeptical. When you pencil it out could you justify it with the US market and then you 
look where else that corn would have to be produced if you didn’t start with mon88 and 
mon89 which are already approved?
Peter Schuerman (Texas A&M Agrilife Research, College Station):  The Arctic apple 
story is fascinating and it’s particularly interesting that such a small company would take 
on that task. Your future plans include some protein traits. How will you finance those 
enterprises in the future?
Carter:  We have to do this with Arctic to prove that we can do it. We have a grower group 
that I am part of that has always known that there is a lot of money in something that 
is new and different. With a GM apple, we aren’t sure if that’s still going to be the case 
because of the consumer push back. We have learned a lot regarding how to do it faster. 
We’ve learned how to negotiate the regulatory process. The science is actually relatively 
straightforward, and the great thing about it is that it works. We will chase the money, I 
guess, and apply for grants and leverage, we’ve been able to leverage our shareholder capital 
about 4 to  from a research point of view. It’s very easy to fund the research. You don’t get 
any leverage on the precommercialization component, which is the shark pit—the chasm 
you have to walk through that is very, very difficult. Dennis called it the Red Zone. The 
Red Zone for him included the regulatory piece. For us it’s more the precommercializa-
tion phase, understanding the industry that you are working in, having an intimate idea 
of whom to talk with and how to sell it and maybe how to get a few key big companies 
involved to help steer that process. In fact, in all of the new traits we are working on, we 
have large tree-fruit-growing companies, usually vertically integrated, that are interested 
in that product and they will help partner in that cost.
Lineberger: So, they are investors?
Carter: They’re not shareholders. It’s fee-for-services-type work.
Schuerman:  Venture capitalists?
Carter: Yes. These are people who got in early before they read the fine print: “Neal, what 
did you talk me into?” My wife and I are the two largest shareholders and so I guess we 
are just stupid or something. We have about 40 shareholders and half of them are fruit 
growers—people who are willing to speculate on being part of something new. I’m lucky. 
I’m involved in some other business activities and I dragged some of those guys in too, 
and maybe they aren’t feeling so lucky, but I’m feeling lucky.
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Purcell:  With the portfolio process, it’s rarely the technical feasibility that kicks things 
out on the vegetable side—insect control, virus control, those kinds of things we know 
we can do. Being with growers pretty much every day the value in there is there but when 
you think about how all the elements in the chain have to come together to do that, and 
then the international elements as I discussed, that’s where it gets really problematic.
Tony Shelton (Cornell University, Ithaca):  We’ve all heard about how great this technol-
ogy is, but the main issue seems to be communication with the consumer. And I see, 
Neal, that you have a nice little friendly label, and people can go to your website and 
learn more about it. What happens if, all of a sudden, you have to slap a label on there 
that says “genetic engineered” and you don’t not have control over the friendliness of the 
message. How will you deal with that?
Carter:  If mandatory labeling laws come in with a skull and crossbones or something, sure 
it’s not going to help. But identifying Arctics as Arctics with point-of-sale literature avail-
able—and these kinds of things—I don’t think it will change much. I think that there is 
going to be fairly widespread understanding that this is a genetically engineered apple.
Shelton: And Rick, what about that for citrus? It’s not going to apply to the fresh market, 
it’s more for the juice.
Kress:  No, it will be fresh as well. Although we are in Florida this is going to be a pro-
cess that is going to have to go through the entire regulatory approval for the United 
States. It will affect all of citrus in all directions. From our perspective, we recognize the 
work that we are going to have, education-wise. With the various research that we have 
going, we are kind of in a horse race. We have several horses that have broken from the 
gate and as we go towards the third pole we will start to narrow that down and when we 
start looking towards the fourth, the finish line, that’s when we will step out and become 
more involved in that overall education process because we will know the direction we 
are going. We can’t work on an education process today with three different directions. 
That won’t work. When we get to the direction we are going in and then we will move 
forward on education before we get commercial.
Christiane Deslauriers (Agriculture and Agrifood Canada, Ottawa): The objection that I 
hear most of the time from industry is the unpredictability of the regulatory system. The 
biggest impediment to progress in this kind of work is not knowing what the regulatory 
system is going to be. Given your experience, do you think it is realistic to ever think you 
will be able to know ahead of time—the question will be knowable ahead of time? And 
to what extent has that applied for each of you?
Kress:  Part of our challenge has been that we are working with a tree. We are not work-
ing with a corn plant, potato or other annual. There is a gap in the information that the 
agencies have. The first time we went to DC and met with the agencies, we went with the 
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intent of asking a lot of questions and we were very open with what we were doing. So, 
we are working very closely with all three. I judge the quality of the meeting that we have 
when we are in DC by the number of questions that I come home with, and generally I 
come home with more questions than answers. That’s okay, because that’s what we have 
to do to get through this. That’s how we are looking at it. We wish there were a template, 
but there isn’t. We are going through step by step, and trying to be proactive.
Purcell:  Roger Beachy talked about the inconsistency on the world stage and that’s where 
we, a global seed company, see much unpredictability. Think about emerging and growth 
markets in Asia market where they might not even have a regulatory system in place. So 
you are developing your product while the regulatory system is being constructed and 
that’s where a lot of the uncertainty comes in because you don’t have harmonization. In 
many cases the rules are being written as people are trying to develop products and that, 
obviously, introduces a lot of uncertainty in when you can expect an approval or even 
what you have to do to put a submission together. 
Carter:  The smaller the company the bigger the uncertainty in terms of risk caused be 
regulatory timelines. You have a burn rate, but you don’t know if it’s going to take two 
years, three years, four years or five years. It’s hard to know when you are going to get 
into the marketplace and start to see return on investments. In January 0, we met 
with APHIS and FDA and a timeline was given. But, you leave the meeting and im-
mediately there is slippage, and then they come out with their new timeline process and 
immediately there is more slippage. Such uncertainty builds risk and, typically, boards of 
directors and shareholders don’t like risk. If you are trying to raise money they are going 
to say, “Yes, but what about the regulatory thing, where are you with that?” And you say, 
“Well I don’t really know. We thought we would be done but we’re not.” These things 
are definitely impediments to raising capital.
Tom Redick (Global Environmental Ethics Counsel, Clayton):  We’ve seen the labeling 
laws in Europe cost us literally billions in trade, measured by European economists who are 
very objective. The Connecticut labeling law has to include at least four states contiguous 
states. Assuming a bunch of states in the northeast enact a GM-labeling law, would that 
significantly impact your ability to go forward with your orange or apple or potato?
Kress:  It’s not going to slow us down because if we don’t find a solution to this disease 
we’re not going to have citrus. That’s the bottom line there. Another thing, which, in a 
backhanded way, is in our favor, we won’t be introducing tomorrow. We’ve got some years 
yet, still involved in this, so we are anticipating that this is all going to get sorted out. 
Again, a lot of companies that market orange juice are interested in how this will play out. 
On one hand we have time, and on the other hand we don’t. It’s all got to work.
Juan Landivar (Texas Agrilife Research, College Station):  I think you said that you have 
until 09 for deregulation. Where are we going to get our orange juice? From Brazil? 
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What is the plan? What is going to happen? Is there any way that the process can be 
accelerated?
Kress:  I didn’t go into all of our research. We have some other approaches that could 
provide interim solutions to shorten that timeline. One has to be optimistic. My board 
of directors asked me one time how we were addressing all of this and I said that I’m 
optimistic six out of seven days. They said, “What day aren’t you?” And I said, “Well, 
that’s the problem, I never know which day it’s going to be.
Tom Turpen (Citrus Research and Development Foundation, Lake Alfred):  For Neal—I 
thought it was brilliant—the selection of the trait and how it benefits the participants 
along the whole value chain. And also the communication of the technology—it was the 
best description of RNAi I’ve ever seen, with the railroad tracks. I wonder if you could 
preview for us the story you will use for the infectious-disease traits, because those will 
be adding a PIP. You did such a good job of communicating your Arctic apple story, how 
will you communicate your infectious-disease traits?
Carter:  I don’t quite have that story mapped out yet, so I can’t answer your question, 
sorry. It would be premature at this stage. But, a couple of things—we go to see US Apple 
in Washington and they say, “Oh, if you had an agronomic trait, we would really like 
it because our growers would be behind it.” And we respond, “Yeah, but consumers are 
the ones you have to please.” So, we are really frustrated by the fact that every industry 
group we meet with—growers, grower/packers, shippers, their industry representative 
groups–they all want agronomic traits, and they are willing to support those and stand 
behind them and promote them and all the rest, so maybe we won’t need to. We chose our 
trait because we felt that we needed to get the consumer on our side and that if we just 
jumped into scab or fire blight right off the start, we would be dead in the water. So they 
will be Arctic plus. They will be non-browning with fire blight resistance, non-browning 
with storage scald resistance—that sort of thing.
Lineberger:  Just to put a little plug in here for Neal—if you go to his website there is a 
link to his TED talk on the integration of biotechnology. It’s fascinating. He uses some 
very common-sense non-technical easy-to-understand approaches.
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